Immutep Limited IMMP
3.25 USD +0.04 (+1.25%)
Regular-session close
3.60 +0.35 +10.77%
After hours · Nov 18, 7:59 PM ET
3.06 Day range 3.50
2.66 52-week range 70.60
- YTD
- +13.64%
- 1 year
- +85.71%
News
globenewswire.com Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma SYDNEY, AUSTRALIA, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a clinical-stage biotechnology company developing novel LAG-3…
benzinga.com Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.
globenewswire.com Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced…benzinga.com Immutep Reports Encouraging EFTISARC-NEO Phase II Sarcoma Survival Data; Efti + KEYTRUDA + Radiotherapy Shows 81.1% 12-Month DFS, 94.1% LRFS And 86.2% DMFS In 38 Patients First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).With a median…
globenewswire.com Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and…
globenewswire.com IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses SYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune…
globenewswire.com Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026 SYDNEY, AUSTRALIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune…benzinga.com Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027 Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials…
benzinga.com Immutep Receives Cash Payment Of €1.36M From French Government Under Tax Incentive Program Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash…
benzinga.com Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced health-related quality of life
defenseworld.net Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average – What’s Next? Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $6.08 and traded as…
globenewswire.com Immutep Receives ~A$0.86 Million R&D Tax Incentive SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune…
defenseworld.net Short Interest in Prima BioMed Ltd (NASDAQ:IMMP) Decreases By 36.4% Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 760,586…
defenseworld.net Prima BioMed (NASDAQ:IMMP) Stock Crosses Above 50 Day Moving Average – Should You Sell? Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.40 and traded as high as $0.41. Prima…
globenewswire.com Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune…
globenewswire.com Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004 SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a…
prnewswire.com Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b)…
gurufocus.com IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm [url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (âImmute
businesswire.com IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)---- $IMMP--IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm.
feeds.newsfilecorp.com Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - July 2, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
globenewswire.com IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm LOS ANGELES, July 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP NEW YORK, July 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are…
globenewswire.com IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) investors of…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP). Such investors are…
feeds.newsfilecorp.com Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - June 30, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
